

Please amend the application as follows:

In the Claims

Please cancel Claims 1-90.

Please add new Claims 91-119.

91. (New) A method of improving memory consolidation in a human having an impairment in memory consolidation, comprising the step of administering an amphetamine to the human in an amount effective to improve memory consolidation in the human, wherein the amphetamine is at least about 90 mole percent 1-amphetamine.

92. (New) The method of Claim 91, wherein the amphetamine is administered in a single dose.

93. (New) The method of Claim 92, wherein the single dose is a dose between about a 0.0001 mg/kg dose to about a 4.0 mg/kg dose.

94. (New) The method of Claim 93, wherein the dose is between about a 0.0001 mg/kg dose to about a 1 mg/kg dose.

95. (New) The method of Claim 92, wherein the single dose is a dose between about a 2.5 mg dose to about a 125 mg dose.

96. (New) The method of Claim 91, wherein the amphetamine is administered in multiple doses.

97. (New) The method of Claim 96, wherein each dose of the multiple doses is administered at a dose between about a 0.0001 mg/kg dose to about a 4.0 mg/kg dose.

A
out

98. (New) The method of Claim 97, wherein the dose is between about a 0.0001 mg/kg dose to about a 1 mg/kg dose.
99. (New) The method of Claim 96, wherein each dose of the multiple doses is administered at a dose between about a 2.5 mg dose to about a 125 mg dose.
100. (New) A method of improving memory consolidation in a human having an impairment in memory consolidation, comprising the step of administering an amphetamine to the human in an amount effective to improve memory consolidation in the human, wherein the amphetamine is at least about 95 mole percent L-amphetamine.
101. (New) The method of Claim 100, wherein the amphetamine is administered in multiple doses.
102. (New) A method of improving memory consolidation in a human having an impairment in memory consolidation, comprising the step of administering an amphetamine to the human in an amount effective to improve memory consolidation in the human, wherein the amphetamine is at least about 99 mole percent L-amphetamine.
103. (New) The method of Claim 102, wherein the amphetamine is administered in multiple doses.
104. (New) A method of improving memory consolidation in a human having an impairment in memory consolidation, comprising the step of administering an amphetamine to the human in an amount effective to improve memory consolidation in the human, wherein the amphetamine is at least about 90 mole percent L-amphetamine and the dose of L-amphetamine administered to the human is between about a 0.0001 mg/kg dose to about a 4.0 mg/kg dose.

105. (New) The method of Claim 104, wherein the amphetamine is administered in multiple doses.

106. (New) A method of improving memory consolidation in a human having an impairment in memory consolidation, comprising the step of administering an amphetamine to the human in an amount effective to improve memory consolidation in the human, wherein the amphetamine is at least about 90 mole percent l-amphetamine and the dose of l-amphetamine administered to the human is between about a 2.5 mg dose to about a 125 mg dose.

107. (New) The method of Claim 106, wherein the amphetamine is administered in multiple doses.

108. (New) A method of improving memory consolidation in a human having an impairment in memory consolidation, comprising the step of administering an amphetamine to the human in an amount effective to improve memory consolidation in the human, wherein the amphetamine is at least about 95 mole percent l-amphetamine and the dose of l-amphetamine administered to the human is between about a 0.0001 mg/kg dose to about 4.0 mg/kg dose.

109. (New) The method of Claim 108, wherein the amphetamine is administered in multiple doses.

110. (New) A method of improving memory consolidation in a human having an impairment in memory consolidation, comprising the step of administering an amphetamine to the human in an amount effective to improve memory consolidation in the human, wherein the amphetamine is at least about 95 mole percent l-amphetamine and the dose of l-amphetamine administered to the human is between about a 2.5 mg dose to about a 125 mg dose.

41 out.

All
cont.

111. (New) The method of Claim 110, wherein the amphetamine is administered in multiple doses.
112. (New) A method of improving memory consolidation in a human having an impairment in memory consolidation, comprising the step of administering an amphetamine to the human in an amount effective to improve memory consolidation in the human, wherein the amphetamine is at least about 99 mole percent l-amphetamine and the dose of l-amphetamine administered to the human is between about a 0.1 mg/kg dose to about 4.0 mg/kg dose.
113. (New) The method of Claim 112, wherein the amphetamine is administered in multiple doses.
114. (New) A method of improving memory consolidation in a human having an impairment in memory consolidation, comprising the step of administering an amphetamine to the human in an amount effective to improve memory consolidation in the human, wherein the amphetamine is at least about 99 mole percent l-amphetamine and the dose of l-amphetamine administered to the human is between about a 2.5 mg dose to about a 125 mg dose.
115. (New) The method of Claim 114, wherein the amphetamine is administered in multiple doses.
116. (New) A method of improving memory consolidation in a human having an impairment in memory consolidation, comprising the step of administering an amphetamine to the human in an amount effective to improve memory consolidation in the human, wherein the amphetamine is between about 90 mole percent l-amphetamine to about 99 mole percent l-amphetamine.

AI
OMI

117. (New) A method of improving memory consolidation in a human having an impairment in memory consolidation, comprising the steps of:
 - a) assessing the degree of impairment in memory consolidation in the human;
 - b) administering an amphetamine to the human in an amount effective to improve memory consolidation in the human, wherein the amphetamine is between about 90 mole percent l-amphetamine to about 99 mole percent l-amphetamine; and
 - b) determining the improvement in memory consolidation after administering the amphetamine to the human.
118. (New) The method of Claim 117, further including the step of comparing the impairment in memory consolidation in the human before administering the amphetamine to the improvement in memory consolidation in the human after administering the amphetamine.
119. (New) The method of Claim 117, wherein the amphetamine is administered in multiple doses.

REMARKS

Restriction Requirement

Applicants elect the claims of Group II (Claims 24-47, 55-78 and 80-87), directed to a process of using the amphetamine. Applicants further elect Group II(a) (Claims 24-47 and 55-78), directed to a method of treating memory impairment with amphetamine and the species l-amphetamine. The claims of Group II(a) are all directed to the elected species. Applicants reserve the right to file a continuing application or take such other appropriate action as deemed necessary to protect the non-elected inventions. Applicants do not hereby abandon or waive any rights in the non-elected inventions.